summit trial tirzepatide results SUMMIT: a 'Huge Win' for HFpEF Patients With Obesity Tirzepatide and the 10‐year predicted

GLP-1R agonism has well-established actions to reduce glucagon secretion in both isolated human islets 28 and in vivo 29 , whereas GIPR agonism increases glucagon secretion in preclinical models 11 and in humans 30

Messenger-RNA changes are not equivalent to protein function or metabolic flux

Collectively, these data support a self-perpetuating chronometabolic cycle in which circadian disruption both drives and is amplified by MASLD, positioning circadian integrity as a mechanistically central and potentially modifiable axis in disease progression

Improved exercise performance: Ratiopharm L-Carnitine 10G Injection may also improve exercise performance by increasing the body's ability to use fat for energy, which can delay the onset of fatigue and improve endurance

I believe GLP-1 medications are generally safe for long-term use, as many studies support their effectiveness and safety profile